arrow
A

Artur Oręziak

national institute of cardiology
H指数:16
被引数:3,531

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM

梗阻性肥厚型心肌病患者报告结局指标的长期影响:FOREST-HCM研究的结果

2026-08-030
OAAI
Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM

Aficamten在非梗阻性肥厚型心肌病患者的安全性与有效性:FOREST-HCM研究96周分析

2025-09-280
OAAI
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten 治疗:有症状性梗阻性肥厚型心肌病

2025-06-190
PRE
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy

阿菲坎坦与丙吡胺联用治疗症状性梗阻性肥厚型心肌病

2025-04-020
OAAI
Efficacy and Safety of Aficamten in Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM Trial

Aficamten在FOREST-HCM试验中,对符合室间隔减容治疗指南适应证患者的疗效与安全性

2024-11-120
PRE
Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy

mavacamten在梗阻性肥厚型心肌病中的长期疗效

2024-09-011
OAAI
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Aficamten在症状性梗阻性肥厚型心肌病中的剂量和安全性: 来自sequoia-hcm的结果

2024-08-064
OAAI
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM

aficamten在非梗阻性肥厚型心肌病患者中的安全性和有效性: forest-hcm的36周分析

2024-07-183
OA
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
2024-05-3052
PRE